Basit öğe kaydını göster

dc.contributor.authorSaatci, I.
dc.contributor.authorYavuz, K.
dc.contributor.authorOzer, C.
dc.contributor.authorGeyik, S.
dc.contributor.authorCekirge, H. S.
dc.date.accessioned2019-12-10T11:31:59Z
dc.date.available2019-12-10T11:31:59Z
dc.date.issued2012
dc.identifier.issn0195-6108
dc.identifier.urihttps://doi.org/10.3174/ajnr.A3246
dc.identifier.urihttp://hdl.handle.net/11655/15982
dc.description.abstractBACKGROUND AND PURPOSE: Flow-diverting devices now offer a new treatment alternative for cerebral aneurysms. We present the results of a large single-center series of patients treated with the PED, including long-term follow-up. MATERIALS AND METHODS: Between November 2008 and September 2011, sidewall aneurysms with a wide neck (>= 4 mm) or unfavorable dome-neck ratio (<= 1.5); large/giant, fusiform, dissecting, blister-like, and recurrent sidewall aneurysms; aneurysms at difficult angles; and aneurysms in which a branch was originating directly from the sac were treated with the FED. Patients were premedicated with dual antiplatelet medications. Data, including demographics, aneurysm features, clinical presentation, complications, results, and follow-up information, for up to 2 years are presented. RESULTS: Two hundred fifty-one aneurysms in 191 patients were treated. Of these, 96 (38.3%) were large or giant (>= 10 mm). In 34/251 (13.5%), PEDs were used for retreatment. Adjunctive coiling was performed in 11 aneurysms (2.1%). The mean number of devices per aneurysm was 1.3. One aneurysm ruptured in the fourth month posttreatment (0.5%), and symptomatic in-construct stenosis was detected in 1 patient (0.5%) treated with percutaneous transarterial angioplasty. Any event rate was 27/191 (14.1%), with a permanent morbidity of 1% and mortality of 0.5%. Control angiography was available in 182 (95.3%) patients with 239 (95.2%) aneurysms. In 121 aneurysms (48.2%), 1- to 2-year control angiography was available. The aneurysm occlusion rate was 91.2% in 6 months, increasing to 94.6%. CONCLUSIONS: Use of the FED is safe, efficacious, and durable in cerebral aneurysm treatment, with low morbidity-mortality and high occlusion rates as confirmed with mid- to long-term control angiography.
dc.language.isoen
dc.publisherAmer Soc Neuroradiology
dc.relation.isversionof10.3174/ajnr.A3246
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectNeurosciences & Neurology
dc.subjectRadiology, Nuclear Medicine & Medical Imaging
dc.titleTreatment Of Intracranial Aneurysms Using The Pipeline Flow-Diverter Embolization Device: A Single-Center Experience With Long-Term Follow-Up Results
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalAmerican Journal Of Neuroradiology
dc.contributor.departmentRadyoloji
dc.identifier.volume33
dc.identifier.issue8
dc.identifier.startpage1436
dc.identifier.endpage1446
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster